What is it about?
Chronic, progressive lung fibrosis is a terminal disease with limited treatment options. We show here that AQX-1125, a SHIP1 activator, can decrease inflammation and fibrosis and improves survival in a mouse model of lung fibrosis.
Featured Image
Read the Original
This page is a summary of: AQX‐1125, small molecule SHIP1 activator inhibits bleomycin‐induced pulmonary fibrosis, British Journal of Pharmacology, August 2017, Wiley,
DOI: 10.1111/bph.13934.
You can read the full text:
Contributors
The following have contributed to this page
